TPBG
GLUE icon

Turning Point Benefit Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Turning Point Benefit Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14
Closed -$219 – 376
2025
Q4 		$219 Hold
14
– – ﹤0.01% 751
2025
Q3 		$105 Buy
+14
New +$74 ﹤0.01% 716

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Turning Point Benefit Group's GLUE Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Monte Rosa Therapeutics (GLUE) in Q1 2026, closing a stake of 14 shares — an estimated $219 sold.

Turning Point Benefit Group first reported a position in GLUE in Q3 2025 and held it in 2 quarters. The position peaked at $219 in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Monte Rosa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 14 Monte Rosa Therapeutics shares in Q1 2026, an estimated $219.
  • Turning Point Benefit Group first reported a position in Monte Rosa Therapeutics in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Monte Rosa Therapeutics position peaked at $219 in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.